Black Diamond Therapeutics Inc (BDTX) concluded trading on Thursday at a closing price of $1.88, with 22.06 million shares of worth about $41.48 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -61.04% during that period and on March 20, 2025 the price saw a gain of about 9.30%. Currently the company’s common shares owned by public are about 56.64M shares, out of which, 43.16M shares are available for trading.
Stock saw a price change of 13.94% in past 5 days and over the past one month there was a price change of -20.68%. Year-to-date (YTD), BDTX shares are showing a performance of -12.15% which decreased to -60.00% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.59 but also hit the highest price of $7.66 during that period. The average intraday trading volume for Black Diamond Therapeutics Inc shares is 2.70 million. The stock is currently trading 0.89% above its 20-day simple moving average (SMA20), while that difference is down -12.77% for SMA50 and it goes to -49.44% lower than SMA200.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) currently have 56.64M outstanding shares and institutions hold larger chunk of about 75.06% of that.
The stock has a current market capitalization of $106.52M and its 3Y-monthly beta is at 2.79. It has posted earnings per share of -$1.27 in the same period. It has Quick Ratio of 4.92 while making debt-to-equity ratio of 0.27. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BDTX, volatility over the week remained 19.72% while standing at 11.03% over the month.
Stock’s fiscal year EPS is expected to rise by 43.16% while it is estimated to decrease by -53.68% in next year. EPS is likely to shrink at an annualized rate of -6.71% for next 5-years, compared to annual growth of -5.22% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Raymond James on July 31, 2024 offering an Outperform rating for the stock and assigned a target price of $20 to it. On June 30, 2023, Stifel Upgrade their recommendations, while on June 28, 2023, H.C. Wainwright Upgrade their ratings for the stock with a price target of $11. Stock get an Outperform rating from Wedbush on June 27, 2023.
